The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
EIA/RIA: Use at a concentration of 3 µg/ml.
WB: Use at an assay dependent dilution. Predicted molecular weight: 55 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Plasma; synthesized in the liver.
Defects in F10 are the cause of factor X deficiency (FA10D) [MIM:227600]. A hemorrhagic disease with variable presentation. Affected individuals can manifest prolonged nasal and mucosal hemorrhage, menorrhagia, hematuria, and occasionally hemarthrosis. Some patients do not have clinical bleeding diathesis.
Belongs to the peptidase S1 family. Contains 2 EGF-like domains. Contains 1 Gla (gamma-carboxy-glutamate) domain. Contains 1 peptidase S1 domain.
The vitamin K-dependent, enzymatic carboxylation of some glutamate residues allows the modified protein to bind calcium. N- and O-glycosylated. The activation peptide is cleaved by factor IXa (in the intrinsic pathway), or by factor VIIa (in the extrinsic pathway). The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.